Patients with multiple myeloma treated with idecabtagene vicleucel, known as “ide-cel,” a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in Blood Advances.
Marijuana’s psychoactive compound may alter brain wiring in adolescents
In a mouse study designed to explore the impact of marijuana’s major psychoactive compound, THC, on teenage brains, Johns Hopkins Medicine researchers say they found
October 25, 2023